Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) EBITDA Margin (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of EBITDA Margin data on record, last reported at 6984.3% in Q1 2025.

  • For Q1 2025, EBITDA Margin changed N/A year-over-year to 6984.3%; the TTM value through Sep 2025 reached 3727.67%, down 772389.0%, while the annual FY2024 figure was 5186.19%, N/A changed from the prior year.
  • EBITDA Margin reached 6984.3% in Q1 2025 per RANI's latest filing, down from 1454.96% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 4642.61% in Q3 2022 and bottomed at 6984.3% in Q1 2025.
  • Average EBITDA Margin over 5 years is 50.49%, with a median of 1036.57% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: plummeted -328585bps in 2023, then crashed -249154bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 268.13% in 2021, then surged by 1831bps to 4642.61% in 2022, then tumbled by -78bps to 1036.57% in 2023, then tumbled by -240bps to 1454.96% in 2024, then plummeted by -380bps to 6984.3% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 6984.3% in Q1 2025, 1454.96% in Q4 2024, and 1036.57% in Q4 2023.